MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Phase 4
Completed
Conditions
Rubella
Varicella
Mumps
Measles
First Posted Date
2007-02-08
Last Posted Date
2017-03-14
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
500
Registration Number
NCT00432731

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Phase 3
Completed
Conditions
Mumps
Measles
Varicella
First Posted Date
2007-02-08
Last Posted Date
2021-10-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
752
Registration Number
NCT00432523

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Phase 3
Completed
Conditions
Migraine
Interventions
Drug: MK0974 50 mg
Drug: MK0974 150 mg
Drug: MK0974 300 mg
First Posted Date
2007-02-07
Last Posted Date
2015-07-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1703
Registration Number
NCT00432237

Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

Phase 3
Completed
Conditions
Mumps
Haemophilus Infections
Varicella
Diphtheria
Pertussis
Measles
Rubella
Poliomyelitis
Tetanus
Hepatitis B
Interventions
Biological: ProQuad®
Biological: Infanrix® hexa
First Posted Date
2007-02-06
Last Posted Date
2018-03-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
955
Registration Number
NCT00432042

An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)

Phase 3
Terminated
Conditions
Obesity Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Interventions
Drug: Taranabant
First Posted Date
2007-02-02
Last Posted Date
2015-02-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
600
Registration Number
NCT00430742

Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease

Phase 2
Terminated
Conditions
Cystic Fibrosis
First Posted Date
2007-01-22
Last Posted Date
2015-04-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
6
Registration Number
NCT00425165

A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

Phase 1
Terminated
Conditions
Neoplasms
First Posted Date
2007-01-22
Last Posted Date
2015-04-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
3
Registration Number
NCT00424775

A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)

Phase 2
Terminated
Conditions
Pain, Postoperative
First Posted Date
2007-01-19
Last Posted Date
2015-11-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
81
Registration Number
NCT00424424

Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)

Phase 2
Completed
Conditions
Glioma
Interventions
Drug: temozolomide
First Posted Date
2007-01-19
Last Posted Date
2017-06-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
40
Registration Number
NCT00424554

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

Phase 3
Completed
Conditions
Coccidioidomycosis
Interventions
Drug: Fluconazole
Drug: Posaconazole
First Posted Date
2007-01-18
Last Posted Date
2017-04-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT00423267
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy